Monoclonal Antibody Tops Placebo for Reducing Migraine Frequency
Humanized mAb directed against pituitary adenylate cyclase-activating polypeptide ligand reduces migraines over four weeks
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.